After an extended period of lockdown, economic stimulus is badly needed.

If the Royals were still being paid by the long-established Civil List, they would not benefit from the energy auction. But in 2012 this changed and the Queen now gets 25 per cent of the estate's profit.

Source: Streetwise Reports   04/23/2020

Global healthcare packaging components manufacturer company West Pharmaceutical Services Inc. (WST:NYSE) today announced financial results for its first quarter ending March 31, 2020 and provided updated full-year 2020 financial guidance.

The company reported that net sales in Q1/20 increased to $491.5 million, a 10.8% increase from $443.5 million in Q1/19. During the same corresponding period, the firm stated that non-GAAP diluted earnings per share (EPS) increased by 36% to $0.99 and non-GAAP adjusted-diluted EPS increased by 36% to $1.01.

West Pharmaceutical Services advised that it is maintaining its FY/20 net sales guidance, which is expected to be in a range of $1.95-1.97 billion. The company stated that it is updating FY/20 adjusted-diluted EPS guidance to a new range of $3.52-3.62, compared to the prior estimated range of $3.45-3.55.

The company's President and CEO Eric M. Green commented, "During these unprecedented times, our priorities are focused on the well-being and safety of our team members as well as ensuring the supply of critical, high-quality components and solutions to our customers...I am extremely pleased that we delivered a strong performance in the first quarter given the challenging environment that the COVID-19 pandemic has had on our customers, our suppliers and our team members. In particular, we continued to deliver strong sales growth in high-value products, as demand trends from our worldwide customer base were similar to trends we saw last year. Our teams are partnering with a broad range of customers working to support efforts to develop solutions that address the global COVID-19 pandemic such as diagnostics, anti-viral therapeutics and vaccines."

The firm outlined sales in the most recent quarter by product line. The company reported that in Q1/20, net sales in its Proprietary Products segment grew by 9.7% to $373.5 million and that this segment "saw good demand for Westar^®, Daikyo^®, NovaPure^® and FluroTec^® components as well as for devices such as Daikyo Crystal Zenith^® syringes and cartridges and our self-injection platforms."

The firm noted that net sales from its Contract-Manufactured Products segment grew by 14.5% to $118.1 million led by sales of components for diagnostic devices and drug-injection delivery devices.

The company added that the Biologics market unit enjoyed double-digit organic sales growth, the Generics market unit achieved high-single digit organic sales growth and the Pharma market unit registered mid-single digit organic sales growth.

The firm additionally noted that during Q1/20 under its share repurchase program, it repurchased 761,500 shares for $115.5 million at an average share price of $151.65.

West Pharmaceutical Services is headquartered in Exton, Pa., roughly 35 miles west of Philadelphia, and is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems.

West Pharmaceutical has market capitalization of around $13.5 billion with approximately 73.84 million shares outstanding. WST shares opened 5.25% higher today at $179.05 (+$8.93, +5.25%) over yesterday's $170.12 closing price and reached a new 52-week high price this morning of $190.27. The stock has traded today between $177.13 and $190.27 per share and is currently trading at $187.04 (+$17.17, +10.11%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

( Companies Mentioned: WST:NYSE, )

Source: Streetwise Reports   05/01/2020

Seattle Genetics Inc. (SGEN:NASDAQ) yesterday announced financial results for the first quarter ended March 31, 2020.

The company also provided an update on commercial results achieved in the quarter for its lead medicines including ADCETRIS® (brentuximab vedotin) and PADCEV^™ (enfortumab vedotin-ejfv) and the U.S. Food and Drug Administration's (FDA) approval and launch of TUKYSA^™ (tucatinib).

The company's President and CEO Clay Siegall, Ph.D., commented, "We have had a remarkable start to 2020, delivering record product sales in the first quarter that are now coming from both ADCETRIS and PADCEV. Notably, strong PADCEV sales in the first full quarter of launch reflect the unmet need among patients with metastatic bladder cancer...With the recent approval of TUKYSA for patients with metastatic HER2-positive breast cancer, we have now launched our third product just four months after our second...We are also preparing for European commercial operations and have hired general managers in major European markets ahead of potential ex-U.S. approvals of TUKYSA. With two new products, growing revenues, and an advancing pipeline of novel cancer programs, we have exciting prospects for future growth."

The company highlighted that ADCETRIS net sales in the U.S. and Canada increased by 22% to $164.1 million in Q1/20, compared to $135 million in Q1/19. The firm indicated that PADCEV net sales in the U.S. reached $34.5 million in Q1/20, which was its first full quarter of commercialization. The company added that royalty revenues in Q1/20 were $20.4 million and collaboration and license agreement revenues in Q1/20 totaled $15.6 million.

The firm reported a net loss for Q1/20 of $168.4 million, or $0.98 per diluted share, compared to net loss of $13.3 million, or $0.08 per diluted share for Q1/19. The company explained that "the net loss in Q1/20 included a net investment loss of $59.1 million primarily associated with its common stock holdings in Immunomedics, which are marked-to-market, compared to a net investment gain of $38.1 million in Q1/19."

The company advised that its TUKYSA was approved by the FDA for patients with HER2-positive metastatic breast cancer who have received one or more prior anti-HER2 regimens in the metastatic setting. The firm mentioned that it also expects to be able to report topline data in late Q2/20 or Q3/20 for the innovaTV 204 pivotal trial of tisotumab vedotin in patients with recurrent and/or metastatic cervical cancer who have relapsed or progressed after standard of care treatment.

The company noted that it is regularly monitoring the effects of the COVID-19 situation and is maintaining its business outlook estimates for FY/20 that it provided previously on February 6, 2020. For FY/20 it expects ADCETRIS net product sales of $675–700 million, royalty revenues of $105–115 million and collaboration and license agreement revenues of $30–50 million. The firm advised that for FY/20 it expects that R&D expenses will range from $860–950 million with SG&A expenses of $475–525 million.

Seattle Genetics is headquartered in Bothell, Wash., and is a global biotechnology company focused on discovering and commercializing cancer medicines.

Seattle Genetics has a market capitalization of around $23.7 billion with approximately 172.5 million shares outstanding. SGEN shares opened 2.75% higher today at $141.00 (+$3.77, +2.75%) over yesterday's $137.23 closing price and reached a new 52-week high price this morning of $157.00. The stock has traded today between $140.05 and $157.00 per share and is currently trading at $148.51 (+$11.28, +8.22%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

( Companies Mentioned: SGEN:NASDAQ, )

Shares of Kraton Corp. traded 24% higher after the specialty polymers and high-value biobased products maker reported that net income in Q1/20 increased to $209.0 million, compared to $13.6 million in Q1/19.

Peter Tabichi, a teacher in remote Kenya who has been giving most of his salary to the poor, became the first African to win the Global Teacher Prize.

Discover how to fully utilize a profitable affiliate program by creating even more income streams from the product you're promoting. You'll have more reach and more market share with these 7 top tips.

Collaborative software platform will enable the electrical products distributor to more easily track, manage, accrue, and claim against rebate agreements with hundreds of suppliers

Investors in Clean Energy Fuels Corp. (NASDAQ:CLNE) had a good week, as its shares rose 6.3% to close at US$2.11...

The analysts might have been a bit too bullish on Consolidated Edison, Inc. (NYSE:ED), given that the company fell...

The hit in mid-March was sudden and dramatic, but there appear to be signs, including from media buyers, that the worst is over.

Please visit Marketing Land for the full article.

Next year, earnings will have the potential to positively surprise the market: Madhu Kela

Bajaj Auto Q3 Earnings: Profit rises 15% YoY to Rs 1,262 crore

PNB Q3 Earnings: PSU lender reports Rs 492 cr loss on higher provisioning

RIL Q4 earnings preview: Here is what to expect

‘Investors focusing on predictability, sustainability and better quality businesses’

BCE INC., parent of CANADA's BELL MEDIA, saw its overall consolidated operating revenues slip 0.9% year-to-year to C$5.68 billion in first quarter 2020, attributed to the COVID-19 … more

Emkay Global expects PVR and Inox Leisure to post steep year-on-year drop in revenues at 19 per cent and 24 per cent, respectively.

FMCG major Hindustan Unilever on Thursday reported a decline of 3.93 per cent in consolidated profit to Rs 1,512 crore for the fourth quarter, impacted by the coronavirus crisis from mid-March.

Most consumer durables companies in India rely on imported components. Poor input supplies since January and later closure of factories, malls, shops and offices due to the lockdown hit consumer demand badly.

The company’s first-quarter earnings report will provide a view of how the pandemic has accelerated trends already working in its favor, and the extent to which coronavirus restrictions on businesses and consumers have boosted Amazon’s sales.

Analysts expected as much, and that's one reason Microsoft's stock is closing in on the all-time high it hit in early February.

The company’s first-quarter earnings report will provide a view of how the pandemic has accelerated trends already working in its favor, and the extent to which coronavirus restrictions on businesses and consumers have boosted Amazon’s sales.

The most active week of the earnings season is on and the rush of quarterly reports Tuesday, 39 in all, captured the maneuvering of companies from almost every sector as they feel their way through an unprecedented economic shockwave. Companies are being affected in different ways but if there’s a common theme, it’s that the […]

The company’s first-quarter earnings report will provide a view of how the pandemic has accelerated trends already working in its favor, and the extent to which coronavirus restrictions on businesses and consumers have boosted Amazon’s sales.

Shares of Brinker International Inc. (EAT) are rising over 15% in pre-market today, after the company reported strong Q3 results.

Shares of wireless communications services provider T-Mobile US, Inc. (TMUS) are rising more than 7% Thursday morning on upbeat first-quarter earnings.

Following the pullback seen in the previous session, stocks have shown another notable move to the downside during trading on Friday. The major averages continue to give back ground after ending Wednesday's trading at their best closing levels in well over a month.

Stocks moved sharply lower over the course of the trading day on Friday, extending the pullback seen in the previous session. With the steep drop on the day, the major averages continued to give back ground after ending Wednesday's trading at their best closing levels in well over a month.

The major U.S. index futures are currently pointing to a lower opening on Friday, with stocks likely to extend the pullback seen in the previous session.

The major U.S. index futures are pointing to a sharply lower open on Wednesday, with stocks likely to give back ground following the rally seen in the previous session.

While reporting its first-quarter financial results on Friday, PPL Corp. (PPL) said that through the end of the first quarter, it remained on track to achieve its fiscal 2020 earnings forecast of $2.40 to $2.60 per share.

Hain Celestial Group, Inc. (HAIN), an organic and natural products company, on Thursday reported net income from continuing operations for the third quarter of $25.04 million or $0.24 per share, up sharply from $8.78 million or $0.08 per share in the prior-year period.

As you might know, Livongo Health, Inc. (NASDAQ:LVGO) just kicked off its latest quarterly results with some very...

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) investors will be delighted, with the company turning in some strong...

It's been a pretty great week for Morphic Holding, Inc. (NASDAQ:MORF) shareholders, with its shares surging 16% to...

Shaw (SJR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.